MDGL logo

MDGL
Madrigal Pharmaceuticals Inc

6,968
Mkt Cap
$12.15B
Volume
114,019.00
52W High
$615.00
52W Low
$265.00
PE Ratio
-41.19
MDGL Fundamentals
Price
$529.76
Prev Close
$529.84
Open
$525.86
50D MA
$465.78
Beta
0.81
Avg. Volume
367,332.68
EPS (Annual)
-$12.85
P/B
20.08
Rev/Employee
$1.05M
$12,423.38
Loading...
Loading...
News
all
press releases
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendatio...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...
PR Newswire·2d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Hennion & Walsh Asset Management Inc. cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,163 shares of the biopha...
MarketBeat·2d ago
News Placeholder
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·6d ago
News Placeholder
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·6d ago
News Placeholder
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation
The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.
Stocktwits·7d ago
News Placeholder
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% Higher - Should You Buy?
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 11.7% - Should You Buy...
MarketBeat·7d ago
News Placeholder
Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·7d ago
News Placeholder
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
Zacks·7d ago
<
1
2
...
>

Latest MDGL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.